Interim decision making in seamless trial designs: An application in an adaptive dose-finding study in a rare kidney...

Area of Science:

• Clinical Trial Design
• Pharmaceutical Development
• Biostatistics

Background:

• Adaptive seamless trial designs merge drug development phases for efficiency.
• Adaptations include dose selection, sample size adjustments, and population enrichment.
• Implementation challenges persist, particularly in interim analysis decision-making.

Purpose of the Study:

• To showcase adaptive features in early-stage drug development using a Phase 2a/2b case study.
• To demonstrate the role of simulations in evaluating adaptive design operating characteristics and decision rules.
• To outline requirements for successful interim analysis decision-making and operational aspects.

Main Methods:

• Utilized a case study of an adaptive seamless proof-of-concept (Phase 2a)/dose-finding (Phase 2b) trial.
• Employed simulations to assess design operating characteristics and define adaptation decision rules.
• Identified key elements for interim analysis decision-making, stakeholder roles, and preplanning.

Main Results:

• Adaptive seamless designs offer potential time and resource savings compared to traditional separate studies.
• Simulations are crucial for understanding design performance and setting decision criteria.
• Successful implementation requires careful planning, stakeholder involvement, and simulation-based tools.

Conclusions:

• Seamless adaptive designs can significantly accelerate drug development.
• Effective implementation hinges on robust simulation, clear decision rules, and proactive operational planning.
• These designs represent a valuable advancement over traditional trial paradigms when meticulously executed.